Clinical Trial Update: Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

View source ↗

Summary

Pfizer's sunitinib (SU011248) has been approved for marketing for use in cytokine-refractory metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Renal Cell Carcinoma Metastatic

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Status: APPROVED_FOR_MARKETING